ELISA and Western blotting analyses revealed that SYXL alleviated eczema-like skin lesions induced by DNCB in animal models, reversed histopathological abnormalities, curbed the expression of pro-inflammatory cytokines IL-1β, IL-6, and TNF-α, and inhibited the phosphorylation of JAK2 and STAT3. Here, JAK2 is linked to Eczematoid dermatitis.